Postprandial lipemia as a cardiometabolic risk factor

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1489-1503

  Pirillo, Angela ^a,b   Norata, Giuseppe Danilo ^a,c,d   Catapano, Alberico Luigi ^b,c  

^a Ospedale Bassini   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chylomicron; Postprandial lipemia; Remnants; VLDL

Indexed keywords

AAV 1LPLS 447X; ALIPOGENE TIPARVOVEC; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CD31 ANTIGEN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; CHYLOMICRON REMNANT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EZETIMIBE; FATTY ACID; FIBRIC ACID DERIVATIVE; FISH OIL; FRUCTOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID ETHYL ESTER; INSULIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTERIAL WALL THICKNESS; CARBOHYDRATE INTAKE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIETARY FIBER; DISORDERS OF LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD COMPOSITION; GENE SILENCING; HEART INFARCTION; HEREDITY; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID COMPOSITION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MENOPAUSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTPRANDIAL STATE; PROMOTER REGION; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SUGAR INTAKE; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERLIPOPROTEINEMIAS; LIFESTYLE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPOPROTEINEMIAS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIFE STYLE; LIPID METABOLISM; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 84904860837     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.909394     Document Type: Review

References (169)

1. McBride PE. Triglycerides and risk for coronary heart disease. JAMA 2007;298:336-8
2. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009;24:345-50
3. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011;31:1716-25
4. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61
5. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36
6. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013;45:1345-52
7. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85
8. Sniderman AD. Postprandial hypertriglyceridemia(s): time to enlarge our pathophysiologic perspective. Eur J Clin Invest 2000;30:935-7
9. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45
10. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002;13:461-70
11. Patel S, Puranik R, Nakhla S, et al. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 2009;204:424-8
12. Norata GD, Pirillo A, Ammirati E, et al. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2012;220:11-21
13. Nakajima K, Nakano T, Tokita Y, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011;412:1306-18
14. Pirillo A, Norata GD, Catapano AL. Production and Metabolism of Triglyceride- Rich Lipoproteins in Both the Normal and Diabetic States. New York: Humana Press, 2014
15. Twickler T, Dallinga-Thie GM, Chapman MJ, et al. Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 2005;7:140-7
16. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009;16:145-54
17. Karpe F, Bell M, Bjorkegren J, et al. Quantification of postprandial triglyceriderich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 1995;15:199-207
18. Schneeman BO, Kotite L, Todd KM, et al. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci USA 1993;90:2069-73
19. Adiels M, Matikainen N, Westerbacka J, et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012;222:222-8
20. Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin Lab Med 2006;26:773-86
21. Ooi EM, Barrett PH, Chan DC, et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008;114: 611-24
22. Hsieh J, Hayashi AA, Webb J, et al. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler Suppl 2008;9:7-13
23. Pastromas S, Terzi AB, Tousoulis D, et al. Postprandial lipemia: an underrecognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 2008;126:3-12
24. Chan DC, Watts GF. Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism 2012;61:3-11
25. Pavlidis AN, Kolovou GD, Anagnostopoulou KK, et al. Postprandial metabolic heterogeneity in men with primary dyslipidaemia. Arch Med Sci 2010;6:879-86
26. Twickler TB, Dallinga-Thie GM, Cohn JS, et al. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004;109:1918-25
27. Cohn JS, McNamara JR, Cohn SD, et al. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29:469-79
28. Puga GM, Meyer C, Everman S, et al. Postprandial lipemia in the elderly involves increased incorporation of ingested fat in plasma free fatty acids and small (Sf 20-400) triglyceride-rich lipoproteins. Am J Physiol Endocrinol Metab 2011;301:E356-61
29. Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev 2004;5(Suppl 1):4-104
30. Su JW, Ugo Nzekwu MM, Ball GD, et al. Postprandial lipemia as an early predictor of cardiovascular complications in childhood obesity. J Clin Lipidol 2009;3:78-84
31. Couillard C, Bergeron N, Prud'homme D, et al. Gender difference in postprandial lipemia: importance of visceral adipose tissue accumulation. Arterioscler Thromb Vasc Biol 1999;19:2448-55
32. van Beek AP, de Ruijter-Heijstek FC, Erkelens DW, et al. Menopause is associated with reduced protection from postprandial lipemia. Arterioscler Thromb Vasc Biol 1999;19:2737-41
33. Westerveld HE. Estrogens and postprandial lipid metabolism. Atherosclerosis 1998;141(Suppl 1):S105-7
34. Pirro M, Lupattelli G, Siepi D, et al. Postprandial lipemia and associated metabolic disturbances in healthy and hyperlipemic postmenopausal women. Metabolism 2001;50:330-4
35. Kolovou GD, Anagnostopoulou KK, Pilatis ND, et al. The influence of natural menopause on postprandial lipemia in heterozygotes for familial hypercholesterolemia. J Womens Health (Larchmt) 2004;13:1119-26
36. Weintraub M, Grosskopf I, Charach G, et al. Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women. Metabolism 1999;48:1193-6
37. Masding MG, Stears AJ, Burdge GC, et al. The benefits of oestrogens on postprandial lipid metabolism are lost in post-menopausal women with Type 2 diabetes. Diabet Med 2006;23:768-74
38. Lopez-Miranda J, Williams C, Lairon D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 2007;98:458-73
39. Heden TD, Liu Y, Sims LJ, et al. Meal frequency differentially alters postprandial triacylglycerol and insulin concentrations in obese women. Obesity (Silver Spring) 2013;21:123-9
40. Murphy MC, Chapman C, Lovegrove JA, et al. Meal frequency; does it determine postprandial lipaemia? Eur J Clin Nutr 1996;50:491-7
41. Peddie MC, Rehrer NJ, Perry TL. Physical activity and postprandial lipidemia: are energy expenditure and lipoprotein lipase activity the real modulators of the positive effect? Prog Lipid Res 2012;51:11-22
42. Hurren NM, Eves FF, Blannin AK. Is the effect of prior exercise on postprandial lipaemia the same for a moderate-fat meal as it is for a high-fat meal? Br J Nutr 2011;105:506-16
43. Athyros VG, Katsiki N, Doumas M, et al. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin 2013;29:1263-74
44. Mero N, Syvanne M, Eliasson B, et al. Postprandial elevation of ApoB-48- containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke. Arterioscler Thromb Vasc Biol 1997;17:2096-102
45. van Tol A, van der Gaag MS, Scheek LM, et al. Changes in postprandial lipoproteins of low and high density caused by moderate alcohol consumption with dinner. Atherosclerosis 1998;141(Suppl 1):S101-3
46. Suter PM, Gerritsen-Zehnder M, Hasler E, et al. Effect of alcohol on postprandial lipemia with and without preprandial exercise. J Am Coll Nutr 2001;20:58-64
47. Mudrakova E, Poledne R, Kovar J. Postprandial triglyceridemia after single dose of alcohol in healthy young men. Nutr Metab Cardiovasc Dis 2013;23:183-8
48. Pownall HJ, Ballantyne CM, Kimball KT, et al. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med 1999;159:981-7
49. Schneider J, Tesdorfpf M, Kaffarnik H, et al. Alteration of plasma lipids and intermediates of lipid metabolism in healthy fasting volunteers by ethanol and fructose. Res Exp Med (Berl) 1976;167:159-70
50. Fielding BA, Reid G, Grady M, et al. Ethanol with a mixed meal increases postprandial triacylglycerol but decreases postprandial non-esterified fatty acid concentrations. Br J Nutr 2000;83:597-604
51. Duez H, Lamarche B, Uffelman KD, et al. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006;26:1357-63
52. Vansant G, Mertens A, Muls E. Determinants of postprandial lipemia in obese women. Int J Obes Relat Metab Disord 1999;23(Suppl 1):14-21
53. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77
54. Guerci B, Verges B, Durlach V, et al. Relationship between altered postprandial lipemia and insulin resistance in normolipidemic and normoglucose tolerant obese patients. Int J Obes Relat Metab Disord 2000;24:468-78
55. Lewis GF, O'Meara NM, Soltys PA, et al. Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab 1990;71:1041-50
56. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
57. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
58. Sarti C, Gallagher J. The metabolic syndrome: prevalence, CHD risk, and treatment. J Diabetes Complications 2006;20:121-32
59. Perez-Caballero AI, Alcala-Diaz JF, Perez-Martinez P, et al. Lipid metabolism after an oral fat test meal is affected by age-associated features of metabolic syndrome, but not by age. Atherosclerosis 2013;226:258-62
60. Jackson KG, Walden CM, Murray P, et al. Greater impairment of postprandial triacylglycerol than glucose response in metabolic syndrome subjects with fasting hyperglycaemia. Metabolism 2013;62:1065-9
61. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, et al. Postprandial lipaemia in menopausal women with metabolic syndrome. Maturitas 2006;55:19-26
62. Khoury DE, Hwalla N, Frochot V, et al. Postprandial metabolic and hormonal responses of obese dyslipidemic subjects with metabolic syndrome to test meals, rich in carbohydrate, fat or protein. Atherosclerosis 2010;210: 307-13
63. Jackson KG, Walden CM, Murray P, et al. A sequential two meal challenge reveals abnormalities in postprandial TAG but not glucose in men with increasing numbers of metabolic syndrome components. Atherosclerosis 2012;220:237-43
64. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, et al. Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis 2005;4:21
65. Tushuizen ME, Pouwels PJ, Bontemps S, et al. Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. Atherosclerosis 2010;211:308-14
66. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001;88:9-15H
67. Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004;89:2153-9
68. Annuzzi G, De Natale C, Iovine C, et al. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24:2397-402
69. Perez-Martinez P, Delgado-Lista J, Perez-Jimenez F, et al. Update on genetics of postprandial lipemia. Atheroscler Suppl 2010;11:39-43
70. Ryan MF, Grada CO, Morris C, et al. Within-person variation in the postprandial lipemic response of healthy adults. Am J Clin Nutr 2013;97:261-7
71. Delgado-Lista J, Perez-Jimenez F, Ruano J, et al. Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men. J Lipid Res 2010;51:63-73
72. Ostos MA, Lopez-Miranda J, Ordovas JM, et al. Dietary fat clearance is modulated by genetic variation in apolipoprotein A-IV gene locus. J Lipid Res 1998;39:2493-500
73. Fisher RM, Burke H, Nicaud V, et al. Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. EARS Group. J Lipid Res 1999;40:287-94
74. Ostos MA, Lopez-Miranda J, Marin C, et al. The apolipoprotein A-IV-360His polymorphism determines the dietary fat clearance in normal subjects. Atherosclerosis 2000;153:209-17
75. Mendoza-Barbera E, Julve J, Nilsson SK, et al. Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia. J Lipid Res 2013;54:649-61
76. Szalai C, Keszei M, Duba J, et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 2004;173:109-14
77. Noto D, Cefalu AB, Cannizzaro A, et al. Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. Atherosclerosis 2009;206:193-8
78. Lopez-Miranda J, Cruz G, Gomez P, et al. The influence of lipoprotein lipase gene variation on postprandial lipoprotein metabolism. J Clin Endocrinol Metab 2004;89:4721-8
79. Groenemeijer BE, Hallman MD, Reymer PW, et al. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation 1997;95:2628-35
80. Jemaa R, Fumeron F, Poirier O, et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Temoin sur l'Infarctus du Myocarde. J Lipid Res 1995;36:2141-6
81. Anagnostopoulou KK, Kolovou GD, Kostakou PM, et al. Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. Lipids Health Dis 2009;8:24
82. Jimenez-Gomez Y, Perez-Jimenez F, Marin C, et al. The -250G/A polymorphism in the hepatic lipase gene promoter influences the postprandial lipemic response in healthy men. Nutr Metab Cardiovasc Dis 2008;18:173-81
83. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 2013;34:1783-9
84. Inazu A, Nakajima K, Nakano T, et al. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis 2008;196:953-7
85. Kolovou G, Anagnostopoulou K, Kostakou P, et al. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin Chem Lab Med 2007;45:1190-8
86. Kolovou GD, Anagnostopoulou KK, Mikhailidis DP. The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms. Open Cardiovasc Med J 2009;3:48-50
87. Delgado-Lista J, Perez-Martinez P, Perez-Jimenez F, et al. ABCA1 gene variants regulate postprandial lipid metabolism in healthy men. Arterioscler Thromb Vasc Biol 2010;30:1051-7
88. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006;367:36-47
89. Rana JS, Boekholdt SM, Kastelein JJ, et al. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr Atheroscler Rep 2012;14:130-4
90. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):E1-40
91. van Diepen JA, Berbee JF, Havekes LM, et al. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 2013;228:306-15
92. Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007;193:321-7
93. Wang YI, Schulze J, Raymond N, et al. Endothelial inflammation correlates with subject triglycerides and waist size after a high-fat meal. Am J Physiol Heart Circ Physiol 2011;300:H784-91
94. Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160-6
95. Alipour A, van Oostrom AJ, Izraeljan A, et al. Leukocyte activation by triglyceride- rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-7
96. Lacroix S, Rosiers CD, Tardif JC, et al. The role of oxidative stress in postprandial endothelial dysfunction. Nutr Res Rev 2012;25:288-301
97. van Oostrom AJ, Sijmonsma TP, Verseyden C, et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 2003;44:576-83
98. Halkes CJ, van Dijk H, de Jaegere PP, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001;21:1526-30
99. Meijssen S, van Dijk H, Verseyden C, et al. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002;22:811-16
100. Norata GD, Pirillo A, Callegari E, et al. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res 2003;59:169-80
101. Norata GD, Grigore L, Raselli S, et al. Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies. J Mol Cell Cardiol 2006;40:484-94
102. Norata GD, Catapano AL. Triglyceride-rich lipoproteins from normotrygliceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns. Circ Res 2007;100:e81
103. Norata GD, Raselli S, Grigore L, et al. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 2009;206:556-62
104. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997;79:350-4
105. Lundman P, Eriksson M, Schenck-Gustafsson K, et al. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997;96:3266-8
106. Marchesi S, Lupattelli G, Schillaci G, et al. Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men. Atherosclerosis 2000;153:397-402
107. Maggi FM, Raselli S, Grigore L, et al. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab 2004;89:2946-50
108. Karpe F, Boquist S, Tang R, et al. Remnant lipoproteins are related to intima- media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001;42:17-21
109. Karpe F, de Faire U, Mercuri M, et al. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middleaged men. Atherosclerosis 1998;141:307-14
110. Boquist S, Ruotolo G, Tang R, et al. Alimentary lipemia, postprandial triglyceride- rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999;100:723-8
111. Ryu JE, Howard G, Craven TE, et al. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 1992;23:823-8
112. Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-6
113. Mori Y, Itoh Y, Komiya H, et al. Association between postprandial remnantlike particle triglyceride (RLP-TG) levels and carotid intima-media thickness (IMT) in Japanese patients with type 2 diabetes: assessment by meal tolerance tests (MTT). Endocrine 2005;28:157-63
114. Ahmad J, Hameed B, Das G, et al. Postprandial hypertriglyceridemia and carotid intima-media thickness in north Indian type 2 diabetic subjects. Diabetes Res Clin Pract 2005;69:142-50
115. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
116. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16
117. Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001
118. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270:65-75
119. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142-52
120. Lekhal S, Borvik T, Nordoy A, et al. Increased postprandial triglyceride-rich lipoprotein levels in elderly survivors of myocardial infarction. Lipids 2008;43:507-15
121. Uiterwaal CS, Grobbee DE, Witteman JC, et al. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med 1994;121:576-83
122. Lekhal S, Borvik T, Nordoy A, et al. Decreased lipoprotein lipase activity and increased postprandial concentrations of triglyceride-rich lipoproteins in offspring of elderly survivors of myocardial infarction. Nutr Metab Cardiovasc Dis 2008;18:700-6
123. Carstensen M, Thomsen C, Gotzsche O, et al. Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. Rev Diabet Stud 2004;1: 175-84
124. Tibolla G, Norata GD, Artali R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011;21:835-43
125. Hovingh GK, Davidson MH, Kastelein JJ, et al. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34:962-71
126. Cabezas MC, de Bruin TW, Westerveld HE, et al. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Intern Med 1998;244:299-307
127. Mamo JC, Smith D, Yu KC, et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur J Clin Invest 1998;28:379-84
128. Cabezas MC, de Bruin TW, Jansen H, et al. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:804-14
129. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011;48:97-113
130. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175-83
131. Cassader M, Gambino R, Musso G, et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001;36:1117-24
132. Musso G, Cassader M, De Michieli F, et al. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012;56:933-42
133. Tinker LF, Parks EJ, Behr SR, et al. (n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal. J Nutr 1999;129:1126-34
134. Slivkoff-Clark KM, James AP, Mamo JC. The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men. Nutr Metab (Lond) 2012;9:9
135. Ooi EM, Lichtenstein AH, Millar JS, et al. Effects of therapeutic lifestyle change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. J Lipid Res 2012;53:1958-67
136. Karjalainen JJ, Kiviniemi AM, Hautala AJ, et al. Effects of exercise prescription on daily physical activity and maximal exercise capacity in coronary artery disease patients with and without type 2 diabetes. Clin Physiol Funct Imaging 2012;32:445-54
137. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455-63
138. King JM, Crouse JR, Terry JG, et al. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med 1994;97:323-31
139. O'Keefe Jr JH, Harris WS, Nelson J, et al. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995;76:480-4
140. Carlson LA, Oro L, Ostman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand 1968;183:457-65
141. Plaisance EP, Mestek ML, Mahurin AJ, et al. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am J Clin Nutr 2008;88:30-7
142. Usman MH, Qamar A, Gadi R, et al. Extended-release niacin acutely suppresses postprandial triglyceridemia. Am J Med 2012;125:1026-35
143. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91
144. Teo KK, Goldstein LB, Chaitman BR, et al. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke 2013;44:2688-93
145. Kolovou GD, Kostakou PM, Anagnostopoulou KK, et al. Therapeutic effects of fibrates in postprandial lipemia. Am J Cardiovasc Drugs 2008;8:243-55
146. Irvin MR, Kabagambe EK, Tiwari HK, et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet 2010;3:462-7
147. Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. The effect of statins on postprandial lipemia. Curr Drug Targets 2007;8:551-60
148. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005;111:2518-24
149. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211-18
150. Nagashima H, Endo M. Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels 2011;26:428-34
151. Chan DC, Watts GF, Barrett PH, et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res 2002;43:706-12
152. Hogue JC, Lamarche B, Deshaies Y, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism 2008;57:246-54
153. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011;217:142-8
154. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, et al. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009;202:216-24
155. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009;39:689-98
156. Tremblay AJ, Lamarche B, Hogue JC, et al. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009;50:1463-71
157. Kikuchi K, Nezu U, Inazumi K, et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 2012;19:1093-101
158. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010;33:1134-9
159. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40-6
160. Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010;11:55-60
161. Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012;97: 1635-44
162. Norata GD, Tibolla G, Catapano AL. Gene silencing approaches for the management of dyslipidaemia. Trends Pharmacol Sci 2013;34:198-205
163. Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, doubleblind, placebo-controlled trial. J Am Coll Cardiol 2013;62:2178-84
164. Furtado JD, Wedel MK, Sacks FM. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. J Lipid Res 2012;53:784-91
165. Meyers C, Gaudet D, Tremblay K, et al. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. J Clin Lipidol 2012;6:266-7
166. Norata GD, Garlaschelli K, Grigore L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009;19:129-34
167. Norata GD, Baragetti I, Raselli S, et al. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 2010;20:56-63
168. Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of
169. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011;9:271-80